MA50435A - Anticorps anti-ligand anti-cd40 thérapeutiques - Google Patents

Anticorps anti-ligand anti-cd40 thérapeutiques

Info

Publication number
MA50435A
MA50435A MA050435A MA50435A MA50435A MA 50435 A MA50435 A MA 50435A MA 050435 A MA050435 A MA 050435A MA 50435 A MA50435 A MA 50435A MA 50435 A MA50435 A MA 50435A
Authority
MA
Morocco
Prior art keywords
antibodies
ligand
therapeutic
therapeutic anti
ligand anti
Prior art date
Application number
MA050435A
Other languages
English (en)
Inventor
Alexey Lugovskoy
Original Assignee
Als Therapy Development Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Development Inst filed Critical Als Therapy Development Inst
Publication of MA50435A publication Critical patent/MA50435A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050435A 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques MA50435A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762510471P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
MA50435A true MA50435A (fr) 2020-09-02

Family

ID=63592816

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050435A MA50435A (fr) 2017-05-24 2018-05-23 Anticorps anti-ligand anti-cd40 thérapeutiques

Country Status (14)

Country Link
US (1) US11384152B2 (fr)
EP (1) EP3630843A2 (fr)
JP (3) JP7766392B2 (fr)
KR (1) KR102840867B1 (fr)
CN (2) CN110662768B (fr)
AU (2) AU2018271915B2 (fr)
CA (1) CA3063730A1 (fr)
GB (1) GB2578037A (fr)
IL (3) IL322942A (fr)
MA (1) MA50435A (fr)
MX (1) MX2023004314A (fr)
RU (2) RU2770209C2 (fr)
SG (1) SG10202111207TA (fr)
WO (1) WO2018217918A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
RS66218B1 (sr) * 2019-07-01 2024-12-31 Tonix Pharma Ltd Anti-cd154 antitela i njihove upotrebe
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2025518096A (ja) * 2022-05-27 2025-06-12 エレドン ファーマシューティカルズ，インコーポレイテッド 筋萎縮性側索硬化症の治療方法
WO2024211211A1 (fr) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Méthodes pour améliorer la survie d'une greffe à l'aide d'anticorps à chaîne gamma du récepteur il-2
WO2025117849A1 (fr) 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Méthodes et compositions pour la prévention du rejet de greffe
WO2025235683A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Procédés et compositions pour la prévention du rejet de greffe
WO2025235670A1 (fr) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Utilisation d'anticorps anti-ligand cd40 pour l'immunosuppression dans une transplantation de cellules d'îlots
CN119823269B (zh) * 2024-12-10 2025-11-07 上海交通大学医学院附属瑞金医院 Cd40配体的抗原表位肽、抗体及应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
ES2143553T3 (es) 1993-09-02 2000-05-16 Dartmouth College Anticuerpos anti-gp39 y sus utilizaciones.
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
CN1247472A (zh) 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
BR9809641A (pt) 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
JP2002510643A (ja) 1998-04-03 2002-04-09 トラスティーズ・オブ・ダートマス・カレッジ 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2390412A1 (fr) 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Traitement de tumeurs malignes des cellules b a l'aide d'anticorps anti-cd40l associes a des anticorps anti-cd20, et/ou chimiotherapie et radiotherapie
WO2001056603A1 (fr) 2000-02-01 2001-08-09 Tanox, Inc. Molecules d'activation des apc se liant au cd40
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
AU6461201A (en) 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040146949A1 (en) 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP1639014B1 (fr) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes
WO2005003174A1 (fr) 2003-07-08 2005-01-13 Genesto A/S Element de liaison a une proteine a d'adhesine de surface pneumocoque
CA2533593A1 (fr) 2003-07-26 2005-02-10 Biogen Idec Ma Inc. Anticorps modifies presentant une affinite de liaison a l'antigene amelioree
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) * 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) * 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006138316A2 (fr) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methodes permettant d'administrer des molecules au systeme nerveux central
WO2007059332A2 (fr) 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Dosages d’agregation plaquettaire
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
US7647438B1 (en) 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
ME00832B (fr) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Protéines de liaison, incluant des anticorps, dérivés d'anticorps et fragments d'anticorps, qui se lient spécifiquement à cd154 et leurs utilisations
EP2158318A2 (fr) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Régions fc simple chaîne, polypeptides de liaison comportant de telles régions, et procédés correspondants
SI2315780T1 (sl) * 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
EP2367849B1 (fr) 2008-12-05 2017-11-01 ALS Therapy Development Institute Méthode pour le traitement des maladies neurodegeneratives
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2625203A1 (fr) * 2010-10-05 2013-08-14 Novartis AG Anticorps anti-il12rbêta1 et leur utilisation dans le traitement des troubles auto-immuns et inflammatoires
WO2012103218A1 (fr) 2011-01-25 2012-08-02 University Of South Florida Modèle transgénique de la maladie d'alzheimer
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
CA2832281C (fr) * 2011-04-04 2019-11-05 Trustees Of Dartmouth College Anticorps anti-cd154 ayant une liaison deterioree au fcr et/ou des proprietes de liaison au complement deterioree et leur utilisation dans des therapies immunologiques
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
CA2843158A1 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques a fc en tandem
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
WO2013169338A1 (fr) 2012-05-11 2013-11-14 Medimmune, Llc Variants de ctla-4
CN105121621B (zh) 2012-10-18 2019-08-02 张永新 用于细胞动静态交替培养的生物反应器系统及其方法
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
CN106132429A (zh) 2014-03-19 2016-11-16 百时美施贵宝公司 使用针对cd40l的域抗体治疗移植物排斥的方法
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
WO2016028810A1 (fr) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anticorps anti-cd40 et leurs utilisations
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체

Also Published As

Publication number Publication date
WO2018217918A3 (fr) 2019-01-17
RU2019143098A (ru) 2021-06-24
CN110662768B (zh) 2024-01-30
AU2018271915B2 (en) 2025-03-27
MX2023004314A (es) 2023-05-04
US11384152B2 (en) 2022-07-12
RU2019143098A3 (fr) 2021-09-20
JP7766392B2 (ja) 2025-11-10
CA3063730A1 (fr) 2018-11-29
JP2020521745A (ja) 2020-07-27
GB201918703D0 (en) 2020-01-29
AU2025204772A1 (en) 2025-07-17
KR102840867B1 (ko) 2025-07-30
IL309444B2 (en) 2026-02-01
JP2023065390A (ja) 2023-05-12
EP3630843A2 (fr) 2020-04-08
US20230048260A1 (en) 2023-02-16
US20200223932A1 (en) 2020-07-16
IL309444A (en) 2024-02-01
IL270729B1 (en) 2025-10-01
WO2018217918A2 (fr) 2018-11-29
IL309444B1 (en) 2025-10-01
IL322942A (en) 2025-10-01
CN110662768A (zh) 2020-01-07
RU2770209C2 (ru) 2022-04-14
IL270729B2 (en) 2026-02-01
SG10202111207TA (en) 2021-11-29
IL270729A (en) 2020-01-30
AU2018271915A1 (en) 2019-11-28
KR20200010294A (ko) 2020-01-30
GB2578037A (en) 2020-04-15
RU2022108410A (ru) 2022-04-05
JP2026050358A (ja) 2026-03-19
CN117843789A (zh) 2024-04-09

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
FR25C1022I2 (fr) Anticorps anti-pd-1
MA53434A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (fr) Anticorps anti-lag-3
MA50435A (fr) Anticorps anti-ligand anti-cd40 thérapeutiques
EP3423089A4 (fr) Anticorps anti-tigit
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49749A (fr) Anticorps anti-cd137
EP3334757A4 (fr) Anticorps anti-tigit
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3297671A4 (fr) Anticorps anti-ror1
EP3507307A4 (fr) Anticorps bispécifiques
MA46272A (fr) Anticorps anti-cd27
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3383915A4 (fr) Anticorps anti-pd-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3526251A4 (fr) Anticorps anti-p53
EP3399992A4 (fr) Anticorps autoréticulants